News from natera, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 16, 2022, 07:30 ET Matthew Rabinowitz, Natera Co-Founder and Executive Chairman of the Board, Makes Additional Investment in Natera

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that Matthew Rabinowitz, co-founder and Executive Chairman of...

May 05, 2022, 16:05 ET Natera Reports First Quarter 2022 Financial Results

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2022...

May 02, 2022, 08:03 ET Natera Announces First Quarter 2022 Earnings Conference Call

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March ...

Apr 26, 2022, 07:33 ET Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD)

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the RenaCARE (Renasight Clinical Application, Review and...

Apr 19, 2022, 07:33 ET Large Real-World Study with Renasight Genetic Test Highlights High Diagnostic Yield for Patients with Chronic Kidney Disease

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced the results of a large, real-world study1 demonstrating a high yield ...

Apr 13, 2022, 07:33 ET Multi-Site Clinical Validation of Prospera Heart Test Demonstrates Outstanding Performance in Assessing Heart Transplant Rejection

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its clinical validation study1 on its donor-derived...

Apr 11, 2022, 07:33 ET Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will present new data relating to its personalized and ...

Apr 07, 2022, 07:33 ET Natera Publishes VALID Study Results for Prospera Lung dd-cfDNA Transplant Rejection Assessment Test

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of the VALID study1, showcasing its Prospera™...

Apr 06, 2022, 07:33 ET Natera Adds to Organ Health Medical Affairs Leadership Team

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the hiring of Sangeeta Bhorade, M.D., as vice president of...

Apr 01, 2022, 07:33 ET Natera Announces Publication Highlighting Importance of Testing Total cfDNA when Monitoring Kidney Transplant Patients with COVID-19 Infection

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, announced the results of a study1 to examine both total and...

Mar 28, 2022, 07:33 ET Natera Listed as One of World's Most Innovative Health Companies by Fast Company

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has been named to Fast Company's annual list of the World's Most Innovative...

Mar 22, 2022, 07:33 ET New Data in Simultaneous Pancreas-Kidney Transplantation Further Demonstrates the Value of Prospera dd-cfDNA Technology

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a study1 reporting on the performance of donor-derived...

Mar 21, 2022, 07:33 ET Natera Announces Updated Signatera™ MRD Data from CIRCULATE-Japan Presented in Plenary Talk at the Society of Surgical Oncology Conference, and Activation of CIRCULATE-US Trial

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new Signatera data from the prospective, multi-center...

Mar 16, 2022, 11:04 ET Roelof Botha, Lead Independent Director of Natera Board, Makes $5 Million Investment in Natera

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that Roelof Botha, lead independent director of Natera's board of...

Mar 15, 2022, 01:14 ET Update on Lanham Act Case Between Natera and CareDx

A jury in Delaware District Court found that both CareDx, Inc. and Natera, Inc. engaged in false advertising – including that CareDx made materially...

Mar 14, 2022, 07:00 ET Natera Executives and Board to Take Pay in Stock Instead of Cash

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that its executive leaders and board of directors have unanimously...

Mar 11, 2022, 07:30 ET Natera Achieves Milestone of Enrolling First 1,000 Patients in its BESPOKE CRC Study

Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a milestone with over 100 sites initiated and 1,000 patients...

Mar 09, 2022, 18:42 ET Natera to Host Special Investor Call in Response to Misleading Short Seller Report

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Mike Brophy, chief financial officer, will provide an...

Mar 09, 2022, 14:33 ET NATERA RESPONDS TO MISLEADING SHORT SELLER REPORT

We disagree with the accuracy of this report which was generated in an attempt to make a quick profit by short sellers Hindenburg Research, who are...

Feb 24, 2022, 16:05 ET Natera Reports Fourth Quarter and Full Year 2021 Financial Results

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended...

Feb 17, 2022, 17:48 ET Natera Announces Fourth Quarter and Fiscal 2021 Earnings Conference Call

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year...

Feb 17, 2022, 08:35 ET Natera Announces Results of Large, Multi-Center Clinical Experience Study Showing Excellent Positive Predictive Value of the Prospera™ Kidney Test

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced the results of a large, real-world study confirming strong...

Feb 15, 2022, 08:35 ET Natera to Participate in Upcoming Investor Conferences

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy,...

Jan 22, 2022, 14:22 ET Landmark CIRCULATE-Japan Study Shows Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced new data recently presented on the clinical...

Jan 19, 2022, 08:33 ET Natera to Present Latest Signatera™ MRD Data in Colorectal and Pancreatic Cancers at the ASCO GI Symposium 2022, and Host Special Investor Call

Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced the company, along with its collaborators,...